ExperimentsThe in vivo anti-tumor experiments were performed in three independent models.ExperimentsThe in vivo anti-tumor experiments

ExperimentsThe in vivo anti-tumor experiments were performed in three independent models.
ExperimentsThe in vivo anti-tumor experiments were performed in three independent models. In the first two models, 1 ?106 B16 cells were implanted subcutaneously into the right flank of C57BL/6 mice. Once the tumor size reached 50 to 100 mm3, mice were randomly assigned to 8 treatment groups (6 mice per group). After establishment of the tumors, the mice of the first modelXiao et al. Molecular Cancer 2010, 9:10 http://www.molecular-cancer.com/content/9/1/Page 12 of7.8. 9. 10.11.12.13.14. 15.16.17.18. 19. 20.21.22.23.24.25.26.27. 28.29.oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res 2008, 14:1228-1238. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB: Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005, 102:14034-14039. Haviv YS, Curiel DT: Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 2001, 53:135-154. Haviv YS, Curiel DT: Engineering regulatory elements for conditionallyreplicative adeno-viruses. Curr Gene Ther 2003, 3:357-385. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, Tighiouart M, Van Meir EG: Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007, 67:6872-6881. Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J, Nery J, Zepeda M, Maneval DC, Demers GW, Ralston R: Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004, 10:7199-7206. Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28499442 JH, Backendorf C, Quax PH, Eb Van der AJ, Noteborn MH: 11-Deoxojervine custom synthesis Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997, 94:5843-5847. Jeurissen SH, Wagenaar F, Pol JM, Eb van der AJ, Noteborn MH: Chicken anemia virus causes apoptosis of thymocytes after in vivo infection and of cell lines after in vitro infection. J Virol 1992, 66:7383-7388. Rohn JL, Noteborn MH: The viral death effector Apoptin reveals tumorspecific processes. Apoptosis 2004, 9:315-322. van der Eb MM, Pietersen AM, Speetjens FM, Kuppen PJ, van de Velde CJ, Noteborn MH, Hoeben RC: Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther 2002, 9:53-61. Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH, Cornelis JJ: Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther 2001, 8:958-965. Goodson AG, Grossman D: Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol 2009, 60:719735. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012. Kirn DH, McCormick F: Replicating viruses as selective cancer therapeutics. Mol Med Today 1996, 2:519-527. Shisler J, Duerksen-Hughes P, Hermiston TM, Wold WS, Gooding LR: Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J Virol 1996, 70:68-77. Wick M, Zubov D, Hagen G: Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999, 232:97-106. Su CQ, Sham J, Xue HB, Wang XH, Chua D, Cui ZF, Peng LH, Li LF, Jiang LH, Wu MC, Qian QJ: Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomeras.